^
    1d
    A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)
    P1/2, N=33, Recruiting, TenNor Therapeutics Inc. | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026 | Completed --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    minocycline
    1d
    Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum and vivax malaria in Eritrea in 2024 (ACTRN12626000256370)
    P4, N=480, Completed, Ministry of Health
    New P4 trial
    3d
    ETV4 Khib Promotes Intrahepatic Cholangiocarcinoma Progression by Suppressing Ferroptosis Through TXNIP Downregulation. (PubMed, Cancer Lett)
    Notably, the small-molecule compound thiostrepton significantly inhibits ETV4 K97-Khib, thereby promoting ferroptosis and suppressing ICC cell migration, invasion, and lung metastasis. Together, our study reveals a novel ETV4 Khib-driven mechanism underlying ferroptosis suppression and malignant progression in ICC, and highlights ETV4 Khib as a potential therapeutic target in cholangiocarcinoma.
    Journal
    |
    HDAC1 (Histone Deacetylase 1) • TXNIP (Thioredoxin Interacting Protein) • ETV4 (ETS Variant Transcription Factor 4)
    |
    thiostrepton (RSO-021)
    3d
    A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)
    P1/2, N=9, Completed, TenNor Therapeutics Inc. | Recruiting --> Completed | N=33 --> 9 | Trial completion date: Aug 2026 --> Jan 2026 | Trial primary completion date: Aug 2026 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    minocycline
    5d
    Identification and functional exploration of hub genes related to energy metabolism in acute myeloid leukemia. (PubMed, Hematology)
    Consequently, lapatinib, gentamicin, etc., were predicted based on the hub genes, and we found that CDH1 was positively correlated with multiple cells, such as NK cells and T cells, and there was the highest positive correlation between CDH1 and NK cells. Correlation of CDH1 with NK cells is discussed. These hub genes offer promising targets for future individualized AML therapy.
    Journal
    |
    CDH1 (Cadherin 1) • CD44 (CD44 Molecule) • GPC3 (Glypican 3) • AGRN (Agrin) • COL4A1 (Collagen Type IV Alpha 1 Chain)
    |
    lapatinib
    6d
    FUR-05-24: A Phase III, randomized, controlled study of furazidin for bacterial vaginosis. (2024-515332-80-00)
    P2/3, N=600, Recruiting, Adamed Pharma S.A. | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head
    7d
    Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication (clinicaltrials.gov)
    P=N/A, N=70, Not yet recruiting, Peking University First Hospital
    New trial
    8d
    Homoharringtonine and Gilteritinib Synergistically Induce Apoptosis and Suppress Viability in FLT3-ITD-Positive AML Cells. (PubMed, Biomedicines)
    The combination enhanced the p53 expression. Our findings elucidate the mechanism underlying this synergistic interaction and underscore the potential of p53 status as a predictive biomarker for identifying patients most likely to benefit from HHT and gilteritinib combination therapy.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8)
    |
    TP53 mutation • FLT3-ITD mutation • TP53 wild-type
    |
    Xospata (gilteritinib) • Synribo (omacetaxine mepesuccinate)
    10d
    CLARI-21-24: An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarithromycin tablets 500 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Clarithromycin 500 mg coated tablets Manufactured by: Sanofi Medley Pharmaceuticals Ltd. Brazilian Industry, in healthy adult, human subjects under fasting condition. (2024-520153-21-00)
    P1, N=52, Active, not recruiting, Sun Pharmaceutical Industries Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    15d
    Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate (clinicaltrials.gov)
    P4, N=40, Recruiting, The University of Texas Health Science Center, Houston | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date • HEOR
    15d
    Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics (clinicaltrials.gov)
    P1, N=42, Recruiting, Case Western Reserve University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    minocycline
    17d
    A conserved eIF1A+ luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. (PubMed, Cell Rep Med)
    In luminal cells, EIF1A knockdown and the translation inhibitor homoharringtonine (HHT) both suppress HIF-1α translation and tumor growth, while promoting infiltration of anticancer immune cells including PD-1- T cells and CD163- macrophages...Collectively, this work defines conserved molecular features across PCa subtypes, providing promising insights for clinical management. This study was registered at Clinicaltrials.gov (NCT06834321).
    Journal
    |
    PD-1 (Programmed cell death 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD163 (CD163 Molecule) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    Synribo (omacetaxine mepesuccinate)